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a b s t r a c t
The aim of this study is to investigate the long-term immunogenicity of inactivated split-virion 2009 pan-
demic inﬂuenza AH1N1 vaccine after a single immunization.We recruited 480 adults, aged 18–60 years, for a
placebo-controlled, observer-masked, single-center clinical study. We randomly assigned subjects into four
groups: 15μg, 30μg and 45μg of hemagglutinin (HA) dosage groups, and a placebo control group. Finally,
259 subjects completed the entire study. The rates of seroconversion and seroprotection and the geometric
mean increase (GMI) fulﬁlled the criteria of the European Medicines Agency (EMEA) for inﬂuenza vaccine
for 180 days after vaccination in all three dosage groups. However, the seroprotection rates of all dosage
groups were below 70% at day 360 post vaccination, while the seroconversion rates and the GMI continued
to meet the licensure criteria at this time point. In conclusion, a single dose of 15μg HA vaccine could induce
a protective immune response persisting for at least six months in adults. This study could be beneﬁcial for
the future development of inﬂuenza vaccines conferring long-term immunity.
c© 2012 Elsevier B.V.
1. Introduction
Inﬂuenza is a serious public health problem, causing severe illness
and death in humans. In April 2009, a new swine-origin inﬂuenza
A (H1N1) virus emerged in Mexico and the United States, and then
spread rapidly tomore than200countries and regions, causinghuman
infections and tens of thousands of deaths throughout theworld [1,2].
This novel H1N1 virus is responsible for the ﬁrst inﬂuenza pandemic
of the 21st century [3].
Vaccines are considered to be one of the most effective tools, not
only to prevent the spread of inﬂuenza virus but also to mitigate the
severity of illness and the impact of the disease [4]. The risk pre-
sented by the pandemic inﬂuenza A (H1N1) virus prompted a new
monovalent vaccine to be actively developed and clinically assessed
by several vaccine manufacturers throughout the world, and mass
immunization programs have been implemented by many countries.
A variety of vaccines are being thoroughly evaluated for their safety
and immunogenicity in humans, including inactivated whole virus
vaccines, split vaccines with or without adjuvant and live attenuated
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vaccines [5,6]. The results of clinical trials showed that these vac-
cines had good levels of safety and that single-dose vaccination could
induce strong immune responses in healthy people [7–11]. Further-
more, the indicators all met the EU criteria for assessing seasonal
inﬂuenza vaccines [12]. It has now been reported by many studies
that 2009 pandemic inﬂuenza A H1N1 vaccine can provide effective
protection in humans [7–11]. Clinical trials were completed in China
in August 2009. In these clinical trials, 15μg of hemagglutinin antigen
as a two-dose regimenwas administered to vaccine subjects of differ-
ent age groups and the results showed that the vaccine was safe and
effective [13]. Despite the fact that the current inﬂuenza epidemic has
reached a peak in many areas and that the incidence rate is now de-
clining, the inﬂuenza A H1N1 (2009) virus continues to cause a threat
and remains the predominant cause of seasonal inﬂuenza virus infec-
tion [14]. The WHO has added the 2009 pandemic inﬂuenza A H1N1
virus to the recommended composition of inﬂuenza virus vaccines
for use as a seasonal inﬂuenza vaccine candidate [15]. Although the
WHO has announced the end of the pandemic of inﬂuenza A H1N1
(2009) virus, we cannot rule out the possibility of local epidemics of
this virus. TheWHO has also advised the continued administration of
the inﬂuenza A H1N1 vaccine. It is important to study the long-term
immunogenicity of the 2009 pandemic inﬂuenza A H1N1 vaccine and
to determine the potential need for re-vaccination during extended
epidemics.
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The primary aim of this study was to investigate the immune re-
sponses and the persistence of immunogenicity induced by a single
dose of the 2009 pandemic inﬂuenza A H1N1monovalent split-virion
vaccine among adults aged 18–60 years. We also compared the ef-
fects of dosage on the long-term immunogenicity and efﬁcacy of the
split-virion H1N1 vaccine, with the aim of determining the optimum
dosage and regimen for the vaccine for long-term immunization.
2. Methods
2.1. Study design
From July 2009 to July 2010, we carried out randomized, double-
blind, single-center clinical trial in Hengdong County of Hunan
Province (China) on 480 subjects. The Center for Disease Control and
Prevention (CDC) in Hunan Province was responsible for the clinical
trial and the CDC inHengdong County participated in the clinical trial.
The studywas sponsored by the Shanghai Institute of Biological Prod-
ucts (China). The CDC in Hunan Province and Hengdong County were
mainly responsible for data collection during the clinical trial. The
Central South University (Changsha, Hunan, China) was responsible
for data analysis and statistical processing. All of the pilot programs,
clinical manuals and other materials used in this study were consis-
tent with the Declaration of Helsinki and the quality control require-
ments for clinical trials, and were approved by the Ethics Committee
of Hunan Province.
All 480 participants received a single dose injection of the vaccine
or a placebo. The immunologic end points were determined by de-
tecting the hemagglutination-inhibition (HI) antibody positive rates
on day 28, day 90, day 180 and day 360. After serum samples were
collected on day 180, the subjects in control group were received a
supplementary injection of vaccine and the serum samples were not
collected on day 360. The subjectsweremonitored and their systemic
and local reactions were recorded after vaccination.
2.2. Vaccines
The inactivated split-virion vaccine against the H1N1 (2009) virus
was developed by the Shanghai Institute of Biological Products, and
the seed virus was prepared from the reassortant vaccine virus
A/California/7/2009 NYMC X-179A, as recommended by the WHO
[16,17]. The vaccine was prepared in embryonated chicken eggs ac-
cording to the standard techniques used in the production of seasonal
inﬂuenzavaccine. Inbrief, theviruswasampliﬁed in chickenembryos,
then harvested and inactivatedwith formaldehyde. The viral cultures
were then concentrated and puriﬁed for use as the ﬁnal vaccine. The
vaccinewas approved for clinical use by theChineseNational Institute
for the Control of Pharmaceutical and Biological Products (China).
The experimental vaccines were split-virus products containing
15μg, 30μg or 45μg of hemagglutinin antigen per dose (0.5ml). The
placebo consisted of phosphate-buffered saline (PBS).
2.3. Participants
All subjects participated voluntarily in the clinical trials and their
written informed consents were obtained once they fully understood
the study procedures. All subjects were 18–60 years old. The main
exclusion criteria included: a history of infection with the 2009 pan-
demic inﬂuenza AH1N1 virus; receipt of any inﬂuenza vaccinewithin
sixmonths; inoculatedwith any other prevention products in the last
week; a history of allergy or contraindications of vaccination.
Injections were given intramuscularly in the deltoid muscle. After
an on-site safety observation within 30min of the injection, subjects
were asked to recorddata on systemic and local adverse reactions at 6,
24, 48 and 72h and on day 7, day 14 and day 21. Serum samples were
collected on day 28, day 90, day 180 and day 360 after vaccination.
2.4. Randomization and masking
We recruited 480 subjects, aged from 18 to 60. Subjects were
randomly divided into four treatment groups in a 1:1:1:1 ratio which
were administered 15μg, 30μg or 45μg of hemagglutinin or placebo,
respectively. Each treatment group comprised 120 subjects with a
male to female ratio of 1:1. The blind testing was designed by a third
party at Central South University, who was not involved in other
elements of the clinical trials.
2.5. Assays
The antibody titers against the vaccine strain were determined
by HI assays of the anti-homologous strain of X-179A, performed
in accordance with established measures using turkey erythrocytes
[18,19]. In brief, sera were ﬁrstly treated with receptor destroy en-
zyme at 36◦C for 16h. The titers of HI antibody that were below the
detection limit (i.e.,<1:10) were recorded as a value of 1:5, and titers
above 1:10,240were recorded as a value of 1:10,240. The seroconver-
sion rate represented a post-vaccination titer ≥1:40 in subjects with
a pre-vaccination titer of<1:10 or a ≥4-fold titer increase in subjects
with a pre-vaccination titer of ≥1:10. All serum samples were as-
sayed in a blinded manner, in duplicate, and were checked in parallel
by the Chinese National Institute for the Control of Pharmaceutical
and Biological Products.
2.6. Statistical analysis
For safety assessments, the frequency, severity, mean time of ap-
pearance and duration of all the local and systemic adverse events
were calculated in all groups in accordance with the requirements
for inﬂuenza vaccines published by the Division of Microbiology and
Infectious Diseases of the US National Institutes of Health [20,21].
For immunogenicity assessments, the seroconversion rate rep-
resented either a post-vaccination titer ≥1:40 (in accordance with
the requirements for seasonal inﬂuenza vaccines by the European
Committee for Proprietary Medicinal Products) in subjects with a
pre-vaccination titer of <1:10 or a ≥4-fold titer increase in subjects
with a pre-vaccination titer of ≥1:10. The seroprotection rate repre-
sented the proportion of subjects with a post-vaccination titer≥1:40.
A seroprotection rate >70% was considered to provide protection. In
addition, the geometric mean increase (GMI) was the ratio of the titer
after vaccination to the titer before vaccination. All the serum data
analyzed in this research were from the subjects who received ﬁve
times blood collections [22].
Hypothesis testing was conducted using two-sided tests, with an
alpha value of 0.05 considered to indicate statistical signiﬁcance. All
statistical analyses were performed using the SPSS software package
(version 11.5).
3. Results
3.1. Study participants
Recruitment visits were attended by 493 participants (Fig. 1). A
total of 480 subjects between 18 and 60 years of age participated in
the clinical trial and 480 serum sampleswere collected initially. Some
subjects were gradually withdrawn from the clinical trial, so only 454
serum samples were collected on day 28, 416 serum samples were
collected on day 90, 377 serum samples were collected on day 180.
In addition, we only collected 259 serum samples in vaccine groups
on day 360, because the subjects in control group were received a
supplementary injectionof vaccine onday180 and the serumsamples
were not collected on day 360. In all vaccine groups, 259 subjects
completed the entire study and provided ﬁve serum samples.
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Fig. 1. Enrollment and follow-up of study participants.
3.2. Safety of the vaccine
The safety and side effects of the vaccine have been reported pre-
viously [13]. Brieﬂy, adverse reactions were only mild or moderate,
and no serious adverse reaction was detected. In addition, pain was
the most frequently reported adverse effect in the local response and
fever was themost frequently reported adverse effect in the systemic
response. No serious adverse event was reported during the entire
study period [13].
3.3. Immune response
Before vaccination, the proportion of subjects showingHI≥1:40 in
all of the dosage groups was 2.27–4.94%. Immune responses were in-
duced in all subjects after vaccination. Onday 28 after vaccination, the
rates of seroconversion and seroprotection in the 15μg group were
96.43% and 95.24%, respectively, the rates in the 30μg group were
98.85% and 97.70%, respectively, and the rates in the 45μg group
were 100.00% and 97.73%, respectively. On day 90 after vaccination,
the rates of seroconversion and seroprotection declined in all of the
vaccine groups. The rates in the 15μg group were 89.29% and 85.71%,
respectively, the rates in the 30μg groupwere 91.95% and 90.80%, re-
spectively, and the rates in the 45μg group were 94.32% and 93.18%,
respectively. On day 180 after vaccination, the rates of seroconver-
sion and seroprotectionwere lower than the rates on day 28, butwere
similar to the rates on day 90. The seroconversion and seroprotection
rates in the 15μg group were 91.67% and 89.29%, respectively, the
rates in the 30μg group were 95.40% and 87.36%, respectively, and
the rates in the 45μg group were 95.40% and 90.91%, respectively.
On day 360 after vaccination, the rates of seroconversion and sero-
protection in all groups were signiﬁcantly lower than the rates on
day 180 ( P<0.01).The seroconversion and seroprotection rates in the
15μg group were 70.24% and 46.43%, respectively, the rates in the
30μg group were 74.71% and 49.43%, respectively, and the rates in
the 45μg group were 81.82% and 55.68%, respectively (Table 1).
Onday28, the geometricmean titer (GMT) of theHI antibody titers
in the three vaccine groupshad increased signiﬁcantly comparedwith
the GMT pre-vaccination ( P<0.01) and the GMT in the placebo group
( P<0.01). Moreover, the GMT in the 45μg group showed a signiﬁcant
difference with that in the 15μg group and the 30μg group, respec-
tively ( P<0.01), but there was no signiﬁcant difference between the
15μg group and the 30μg group. On day 90, the GMT of the HI an-
tibody titers in the three vaccine groups had declined signiﬁcantly
compared with that on day 28 ( P<0.01). Moreover, the GMT in the
45μg group showed a signiﬁcant difference with that of the 15μg
group ( P<0.01). On day 180, the GMT of the HI antibody titers was
lower than that on day 90 in the three vaccine groups, but showed
no signiﬁcant differences. However, the GMT was signiﬁcantly lower
than that on day 28 ( P<0.01). On day 360, the GMT was signiﬁcantly
lower than before in all groups. The differences between groups on
day 90, day 180 and day 360were similar,with only theGMTbetween
the 15μg group and the 45μg group showing a signiﬁcant difference
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Table 1
Proportion of participants with seroprotection and seroconversion in the various groups.
Dose Baseline 28 days after injection 90 days after injection 180 days after injection 360 days after injection
SP rate SC rate SP rate SC rate SP rate SC rate SP rate SC rate SP rate
Number of participants (Percentage, 95% CI)
Placebo
(n=81)
4 (4.9,
1.4–12.2)
4 (4.9,
1.4–12.2)
6 (7.4,
2.8–15.4)
2 (2.5,
0.3–8.6)
4 (4.9,
1.4–12.2)
17 (21.0,
12.7–31.5)
19 (23.5,
14.8–34.2)
– –
15μg (n=84) 4 (4.8,
1.3–11.8)
81 (96.4,
89.9–99.3)a
80 (95.2,
88.3–98.7)a
75 (89.3,
80.6–95.0)a
72 (85.7,
76.4–92.4)a
77 (91.7,
83.6–96.6)a
75 (89.3,
80.6–95.0)a
59 (70.2,
59.3–79.7)
39 (46.4,
35.5–57.7)
30μg (n=87) 3 (3.4,
0.7–9.8)
86 (98.9,
93.8–100.0)a
85 (97.7,
92.0–99.7)a
80 (92.0,
84.1–96.7)a
79 (90.8,
82.7–96.0)a
83 (95.4,
88.6–98.7)a
76 (87.4,
78.5–93.5)a
65 (74.7,
64.3–83.4)
43 (49.4,
38.5–60.4)
45μg (n=88) 2 (2.3,
0.3–8.0)
88 (100.0,
95.9–100.0)a
86 (97.7,
92.0–99.7)a
83 (94.3,
87.2–98.1)a
82 (93.2,
85.8–97.5)a
84 (95.5,
88.8–98.8)a
80 (90.9,
82.9–96.0)a
72 (95.5,
88.8–98.8)
49 (55.7,
44.7–66.3)
Seroprotection (SP) was deﬁned as an HI titer of no less than 1:40; seroconversion (SC) was deﬁned as an increase in the HI titer by a factor of four or more.
a P<0.05 compared with the placebo.
Table 2
Geometric mean titer (GMT) and the geometric mean increase (GMI) in the various groups.
Dose Baseline 28 days after injection 90 days after injection 180 days after injection 360 days after injection
GMT (95% CI) GMT (95% CI) GMI (95% CI) GMT (95% CI) GMI (95% CI) GMT(95% CI) GMI (95% CI) GMT (95% CI) GMI (95% CI)
Placebo
(n=81)
6.1 (5.3–7.0) 7.4 (6.3–8.7) 1.2 (1.1–1.4) 6.3 (5.5–7.2) 1.4 (1.0–1.1) 12.6
(9.6–16.5)
2.0 (1.6–2.7) – –
15μg (n=84) 6.6 (5.8–7.2) 249.8
(189.6–
329.2)a
38.1
(28.6–50.6)a
100.6 (75.1–
134.8)a
15.4
(11.5–20.6)a
105.9 (81.7–
137.4)a
16.1
(12.4–21.0)a
28.3
(23.9–33.5)
4.3 (3.6–5.1)
30μg (n=87) 6.0 (5.4–6.7) 343.8
(259.5–
455.5)a
57.2
(43.5–75.4)a
123.7 (93.3–
164.1)a
20.6
(15.6–27.3)a
119.2 (90.3–
157.3)a
19.8
(15.3–25.8)a
28.0
(23.3–33.6)
4.7 (3.8–5.7)
45μg (n=88) 6.2 (5.6–6.9) 555.4
(427.5–
721.6)abc
89.1 (68.1–
116.5)abc
188.8
(143.9–
247.9)abc
30.3 (23.0–
39.8)abc
147.9
(114.6–
190.9)a
23.7
(18.1–31.1)a
36.7 (30.7–
43.8)bc
5.9 (4.8–7.2)bc
a P<0.05 compared with the placebo.
b P<0.05 compared with the 15μg dose group.
c P<0.05 compared with the 30μg dose group.
Fig. 2. Reverse cumulative distribution curves of the antibody titers against H1N1
virus on 0, 28, 90,180 and 360 days after injection. The limit of detection was a titer of
1:5. Titers are expressed as the reciprocal of the dilution.
( P<0.01) (Table 2; Figs. 2 and 3).
In the placebo group, the GMT of the HI antibody titers on day
28 and day 90 showed no signiﬁcant difference with the GMT pre-
vaccination. However, the proportion of HI ≥1:40 (23.46%, 95% CI
14.75–34.18) and the GMT on day 180 had increased signiﬁcantly
compared with the values pre-vaccination and on day 28 and day 90
( P<0.01). Meanwhile, the seroprotection rate was 4.94% on day 0;
the rates of seroconversion and seroprotection were 4.94% and 7.41%,
respectively, on day 28; the rates were 2.47% and 4.94%, respectively,
on day 90 and the rates were 20.98% and 23.46%, respectively, on day
180. All of the above data suggested that about 20% of the subjects
may have been infected the 2009 pandemic inﬂuenza A H1N1 virus
during the entire clinical trial. In February 2010, the 2009 pandemic
inﬂuenza A H1N1 virus was still a threat in China. Taking into account
the safety of subjects, after the serum samples were collected on day
180, the subjects in control group were received a supplementary
injection of vaccine (15μg) and on day 360 after immunization, we
did not collect the serum samples in control group.
In summary, in the subjects administered a single dose of vac-
cine, regardless of the dosage (15μg, 30μg or 45μg), could all induce
long-term immune response and six months after immunization, the
rates of seroconversion and seroprotection and the GMI met the re-
quirements speciﬁed by the EuropeanMedicines Agency (EMEA). The
results showed that the vaccine could provide six months at least
long-termprotection, and provide only partial protection after twelve
months.
4. Discussion
In this study, we investigated the long-term immunogenicity of
inactivated split-virion 2009 pandemic inﬂuenza A H1N1 vaccine in
adults aged 18–60 years, 360 days post a single immunization.We re-
cruited 480 adults for a placebo-controlled, observer-masked, single-
center clinical study. Finally, 259 subjects completed the entire study.
This study demonstrated that a single dose of vaccine could induce
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Fig. 3. Reverse cumulative distribution curves of the antibody titers against H1N1
virus in the different dosage groups. The limit of detection was a titer of 1:5. Titers are
expressed as the reciprocal of the dilution
long-term immunity persisting for at least six months, protection
waned signiﬁcantly 1 year after vaccination suggesting the need for a
booster vaccine.
The inﬂuenza epidemic may continue for several years, it is im-
portant to explore the persistence of the antibody response induced
by a single dose of the 2009 pandemic inﬂuenza A H1N1 vaccine in
long term. Martin et al. [23] reported the generation of long-term
immunity at the mucous membranes in a mouse model 120 days
after immunization with the inactivated inﬂuenza vaccine contain-
ing adjuvant, and protection against challenge with a lethal dose of
the virus. Ferguson et al. [24] demonstrated that a single dose of the
3.75μg HA AS03A-adjuvanted H1N1 2009 inﬂuenza vaccine could in-
duce long-term persistence of the immune response until at least six
months after one dose in subjects aged 18–60 and >60 years. In ad-
dition, Nassim et al. [25] demonstrated that a single dose of 3.75μg
of MF59-adjuvanted inﬂuenza vaccine in adults can provide effec-
tive protection for upto ten months. In view of the inﬂuenza vaccines
without adjuvant were used worldwide, so we carried out the clin-
ical trial with different doses of inﬂuenza A H1N1 vaccine without
adjuvant in the adult population for investigation on the long-term
immune response.
In this study, the GMT of the HI antibody 90 days after immuniza-
tion had decreased signiﬁcantly in all of the vaccine groups compared
with 28 days after immunization. Six months after immunization, al-
though the GMT decreased signiﬁcantly, the rates of seroconversion
and seroprotection remained high, which were above the standards
required by the EMEA (the percentage of subjects achieving serocon-
version for HI antibody should be ≥40%; GMI should be >2.5; and
the percentage of subjects achieving seroprotection for HI antibody
should be >70%). The results in our study are consistent with the
studies of Lai et al. [26] and Ferguson et al. [24]. In a randomized
clinical trial by Lai et al. [26] 218 participants aged 18–60 years were
recruited and were vaccinated with split-virion 2009 pandemic in-
ﬂuenza vaccine without adjuvant. The results showed that the rate
of seroprotection remained 76.8% of the participants who received a
single dose of 15μg hemagglutinin antigen six months post vaccine.
Similar results of immune responses were also observed by Ferguson
et al. [24].
However, the seroprotection rates of all dosage groups were be-
low 70% on day 360 post vaccination, while the seroconversion rates
and the GMI continued to meet the licensure criteria at this time
point. In addition, the GMT of HI antibodies produced in the vari-
ous groups increased in a dose-dependent manner, with the highest
dose of 45μg group induced the strongest HI antibody response dur-
ing these twelve months, which demonstrated that a higher dose of
vaccine can induce stronger antibody responses in humans. How-
ever, twelve months post-vaccination, the higher dose groups (30μg
and 45μg) did not displaymuch improvement in their seroprotection
rateswhichdid not fulﬁll the criteria of EMEA, indicating that vaccina-
tion once with a high dose could not improve the seroprotection rate
effectively for long term. Therefore, healthy adults vaccinated with
a 15μg single dose of the 2009 pandemic inﬂuenza A H1N1 vaccine
have the potential to resist virus infection after six months without
booster immunizations.
With respect to the safety of the vaccine, the Chinese CDC have
summarized the clinical adverse-reaction results of the H1N1 in-
ﬂuenza virus split vaccine developed by the 10 domestic Chinese
inﬂuenza vaccine manufacturers and reported them in a paper by
Liang et al. [13] which includes the clinical adverse-reaction results
of our vaccine. The results showed that, after vaccination, in all groups,
adverse reactions were only mild or moderate, without serious ad-
verse reactions, which proved our vaccinewas safe. Since the purpose
of this study is to investigate the long-term immunogenicity of the
H1N1 inﬂuenza virus split vaccine, we did not describe the clinical
adverse-reaction results of our vaccine in detail here.
Our investigations on the long-term protection induced by the
2009 pandemic inﬂuenza A H1N1 vaccine showed that large-scale
vaccination with a 15μg single dose of the split vaccine could pro-
vide protection in the human population during the epidemic period.
The vaccine could induce sufﬁcient protective immunity last for six
months. However, one year after immunization, the three dosage
groups (15μg, 30μg and 45μg) all provided only partial protection.
Since the 45μg and30μgdoses of the split vaccine also couldnotmeet
the requirement of EMEA, the guideline of a 15μg dose of the split
vaccine is correct and one year later, revaccination may be needed.
The results of this study are therefore promising for the future devel-
opment and production of inﬂuenza vaccines.
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